NES
CTIC

New England Securities’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

New England Securities’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2
Closed – – 1807
2014
Q3 		$0 Hold
2
– – ﹤0.01% 1843
2014
Q2 		$0 Hold
2
– – ﹤0.01% 1933
2014
Q1 		$0 Hold
2
– – ﹤0.01% 1907
2013
Q4 		$0 Buy
+2
New +$36 ﹤0.01% 1808

Other funds holding CTIC

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

New England Securities's CTIC Position: Q4 2014 in Review

New England Securities sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2014, closing a stake of 2 shares.

New England Securities first reported a position in CTIC in Q4 2013 and held it in 4 quarters. The position peaked at $0 in Q3 2014. 90 funds tracked by Wall St. Rank hold CTIC as of Q4 2014.

  • New England Securities reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2014 after selling out during the quarter.
  • New England Securities sold 2 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2014.
  • New England Securities first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2013 and held it in 4 quarters.
  • New England Securities's CTI BioPharma Corp. (DE) Common Stock position peaked at $0 in Q3 2014.
  • 90 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2014.

Based on New England Securities's 13F filing for Q4 2014, filed 26 Jan 2015.